Skip to main content
Premium Trial:

Request an Annual Quote

RareCyte CyteFinder II and CyteFinder II HT

RareCyte is introducing its CyteFinder II and CyteFinder II HT instruments, next-generation versions of the company's CyteFinder instruments for multi-omic liquid biopsy and tissue research in clinical labs. Both instruments perform rapid, whole-slide imaging in seven fluorescence channels as well as brightfield for immunofluorescence, immunohistochemistry, and H&E.

CyteFinder II offers researchers a complete workflow in a single platform for imaging through cell retrieval of both liquid biopsy and tissue samples. The integrated CytePicker Retrieval Module enables discovery research by providing image-guided cell retrieval for high-depth sequencing. This workflow can be used for circulating tumor cell mutational analysis, RNA-based T-cell receptor discovery, and differential expression analysis of tissue microenvironments.

CyteFinder II HT meets the demand of high-volume pathology and liquid biopsy labs with hands-free, rapid, whole-slide scanning of up to 80 slides and a barcode-driven workflow for sample tracking. The machine learning-driven workflow for rare cell detection and automated tissue finding make CyteFinder II HT ideal for clinical researchers performing either cellular or tissue-based multiplexed analysis.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.